StreetInsider.com News Articles

Form 4 ANI PHARMACEUTICALS INC For: Aug 19 Filed by: Gosebruch Henry O

Thu, 27 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260827/26990337.html

Form 4 ANI PHARMACEUTICALS INC For: Aug 19 Filed by: Gosebruch Henry O

Thu, 27 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260827/26990337.html

Form 3 ANI PHARMACEUTICALS INC For: Aug 19 Filed by: Gosebruch Henry O

Thu, 27 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260827/26990306.html

Form 3 ANI PHARMACEUTICALS INC For: Aug 19 Filed by: Gosebruch Henry O

Thu, 27 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260827/26990306.html

Form 4 ANI PHARMACEUTICALS INC For: Aug 25 Filed by: Lalwani Nikhil

Wed, 26 Aug 2026 18:15:00 -0400

si-local-file:///var/storage/secattach/20260826/26983095.html

Form 4 ANI PHARMACEUTICALS INC For: Aug 25 Filed by: Lalwani Nikhil

Wed, 26 Aug 2026 18:15:00 -0400

si-local-file:///var/storage/secattach/20260826/26983095.html

Form 144 ANI PHARMACEUTICALS INC Filed by: Lalwani Nikhil

Tue, 25 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260825/26975314.html

Form 144 ANI PHARMACEUTICALS INC Filed by: Lalwani Nikhil

Tue, 25 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260825/26975314.html

Form 8-K ANI PHARMACEUTICALS INC For: Aug 19

Mon, 24 Aug 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260824/26964083.html

Form 8-K ANI PHARMACEUTICALS INC For: Aug 19

Mon, 24 Aug 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260824/26964083.html

ANI Pharmaceuticals adds Henry Gosebruch to its board

Mon, 24 Aug 2026 06:55:14 -0400

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) appointed Henry Gosebruch to its board of directors, effective August 19, 2026, according to a company statement.

Gosebruch currently serves as chief executive officer of Lakefront Biotherapeutics NV, formerly known as Galapagos NV, a position he has held since May 2025. Before that, he was president and chief executive officer of Neumora Therapeutics, Inc. from July 2023 to February 2025.

From 2015 to 2023, Gosebruch was executive vice president and chief strategy officer at AbbVie, where he oversaw corporate strategy, business development, and mergers and acquisitions. During that period, the group completed more than 100 transactions and

ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors

Mon, 24 Aug 2026 06:55:00 -0400

– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company –

PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today reported the addition of Henry Gosebruch to its Board of Directors effective August 19, 2026. Mr. Gosebruch brings over 30 years of corporate strategy, business development and finance experience across the biopharmaceutical sector.

“We are excited to add Henry to our Board of Directors during this pivotal moment for the Company,” stated Thomas (Tom) J. Haughey, Chairman of the Board of ANI.

ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors

Mon, 24 Aug 2026 06:55:00 -0400

– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company –

“We are excited to add Henry to our Board of Directors during this pivotal moment for the Company,” stated Thomas (Tom) J. Haughey, Chairman of the Board of ANI.

ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors

Mon, 24 Aug 2026 06:55:00 -0400

– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company –

“We are excited to add Henry to our Board of Directors during this pivotal moment for the Company,” stated Thomas (Tom) J. Haughey, Chairman of the Board of ANI.

ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors

Mon, 24 Aug 2026 06:55:00 -0400

– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company –

“We are excited to add Henry to our Board of Directors during this pivotal moment for the Company,” stated Thomas (Tom) J. Haughey, Chairman of the Board of ANI.

Form 4 ANI PHARMACEUTICALS INC For: Aug 13 Filed by: Cook Meredith

Thu, 13 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260813/26921937.html

Form 4 ANI PHARMACEUTICALS INC For: Aug 13 Filed by: Cook Meredith

Thu, 13 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260813/26921937.html

Form 4 ANI PHARMACEUTICALS INC For: Aug 10 Filed by: Gutwerg Ori

Tue, 11 Aug 2026 20:57:00 -0400

si-local-file:///var/storage/secattach/20260811/26907607.html

Form 4 ANI PHARMACEUTICALS INC For: Aug 10 Filed by: Gutwerg Ori

Tue, 11 Aug 2026 20:57:00 -0400

si-local-file:///var/storage/secattach/20260811/26907607.html

ANI Pharmaceuticals (ANIP) PT Lowered to $119 at Guggenheim

Mon, 10 Aug 2026 07:39:43 -0400

(Updated - August 10, 2026 7:39 AM EDT)

Guggenheim analyst Vamil Divan lowered the price target on ANI Pharmaceuticals (NASDAQ: ANIP) to $119.00 (from $124.00) while maintaining a Buy rating.

The analyst commented: "We are updating our ANIP company model following the company's 2Q 2026 earnings and our follow-up conversation with management. The company reported overall 2Q 2026 results that were ahead of expectations, with the upside driven primarily by Generics and Brand Royalties and Other Revenues. However, while FY 2026 guidance for total net revenues, EBITDA, and EPS were maintained, the company's 2Q 2026 Cortrophin sales were at the very low

ANI Pharmaceuticals (ANIP) PT Lowered to $119 at Guggenheim

Mon, 10 Aug 2026 07:39:43 -0400

(Updated - August 10, 2026 7:39 AM EDT)

Guggenheim analyst Vamil Divan lowered the price target on ANI Pharmaceuticals (NASDAQ: ANIP) to $119.00 (from $124.00) while maintaining a Buy rating.

ANI Pharmaceuticals (ANIP) PT Lowered to $90 at Canaccord

Mon, 10 Aug 2026 07:21:48 -0400

(Updated - August 10, 2026 7:21 AM EDT)

Canaccord analyst Gary Newman lowered the price target on ANI Pharmaceuticals (NASDAQ: ANIP) to $90.00 (from $91.00) while maintaining a Hold rating.

The analyst commented: "2Q had a slight beat on revenue though EPS fell short, and key growth driver Cortrophin missed with that product's full-year guidance taken down modestly. Cortrophin was $4M light in 2Q, and full-year Cortrophin guidance was lowered by $20-25M from the 1H underperformance (still forecast to grow 50-55% y/ y). ANIP stressed its confidence in the acceleration of Cortrophin in 2H largely from the meaningfully expanded sales force for

ANI Pharmaceuticals (ANIP) PT Lowered to $90 at Canaccord

Mon, 10 Aug 2026 07:21:48 -0400

(Updated - August 10, 2026 7:21 AM EDT)

Canaccord analyst Gary Newman lowered the price target on ANI Pharmaceuticals (NASDAQ: ANIP) to $90.00 (from $91.00) while maintaining a Hold rating.

ANI Pharma (ANIP) Tops Q2 EPS by 18c ; Offers Guidance

Fri, 07 Aug 2026 07:34:48 -0400

ANI Pharma (NASDAQ: ANIP) reported Q2 EPS of $2.21, $0.18 better than the analyst estimate of $2.03. Revenue for the quarter came in at $266 million versus the consensus estimate of $262.14 million.

FY 2026 Outlook:-

Revenue between $1.08 billion to $1.14 billion vs consensus $1.12 billion.
EPS between $9.19 to $9.69 vs consensus $9.42.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

Form 10-Q ANI PHARMACEUTICALS INC For: Jun 30

Fri, 07 Aug 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20260807/26887352.html